Cargando…
HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
BACKGROUND: Patients with non‐small cell lung cancer (NSCLC) harboring activating EGFR mutations are sensitive to epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) but inevitably develop resistance to the inhibitors mostly through acquisition of the secondary T790M mutation. Al...
Autores principales: | Watanabe, Sho, Goto, Yasushi, Yasuda, Hiroyuki, Kohno, Takashi, Motoi, Noriko, Ohe, Yuichiro, Nishikawa, Hiroyoshi, Kobayashi, Susumu S., Kuwano, Kazuyoshi, Togashi, Yosuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919131/ https://www.ncbi.nlm.nih.gov/pubmed/33471376 http://dx.doi.org/10.1111/1759-7714.13839 |
Ejemplares similares
-
Novel agents and strategies for overcoming EGFR TKIs resistance
por: Niu, Fei-Yu, et al.
Publicado: (2014) -
Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018) -
Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017) -
EGFR-TKIs resistance via EGFR-independent signaling pathways
por: Liu, Qian, et al.
Publicado: (2018) -
Circulating cell-free plasma tumour DNA shows a higher incidence of EGFR mutations in patients with extrathoracic disease progression
por: Seki, Yoshitaka, et al.
Publicado: (2018)